Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity (2010 - 2026)

Whitehawk Therapeutics (WHWK) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $127.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 45.63% year-over-year to $127.2 million; the TTM figure through Mar 2026 stood at $625.9 million (up 27.31% YoY), while the FY2025 annual figure was $150.8 million, up 114.49% from the prior year.
• Liabilities and Shareholders Equity slipped to $127.2 million in Q1 2026 per WHWK's latest filing, from $150.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $234.0 million in Q1 2025 and bottomed at $70.3 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $145.4 million across 5 years, with a median of $142.3 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 245.76% — and 2024, when it tumbled 46.9%.
• Whitehawk Therapeutics' Liabilities and Shareholders Equity stood at $184.2 million in 2022, then slipped by 28.12% to $132.4 million in 2023, then plunged by 46.9% to $70.3 million in 2024, then soared by 114.49% to $150.8 million in 2025, then declined by 15.65% to $127.2 million in 2026.
• Business Quant data shows WHWK's Liabilities and Shareholders Equity at $127.2 million in Q1 2026, $150.8 million in Q4 2025, and $167.0 million in Q3 2025.